Global Atrial Fibrillation Drugs Market Research Report 2026

Atrial Fibrillation Drugs Market

Atrial fibrillation (AF) is one of the most common arrhythmias in clinical practice. The occurrence of AF can increase complications such as thromboembolism and heart failure, accelerate the progression of the disease and increase mortality. Symptoms of palpitations, shortness of breath and fatigue caused by AF also seriously affect the quality of life of patients. The goals of drug treatment for atrial fibrillation (AF) are mainly to prevent stroke, control heart rhythm and heart rate, and relieve AF symptoms. Common categories of AF drugs include anticoagulants, antiarrhythmic drugs and heart rate control drugs. AF drugs are mainly used to treat atrial fibrillation, a common arrhythmia that can have a serious impact on the quality of life and prognosis of patients. In recent years, with the deepening of cardiovascular disease research, the research and development of AF drugs has made significant progress. At present, AF drugs include not only traditional antiarrhythmic drugs, but also new targeted drugs, such as potassium channel blockers, sodium channel blockers, etc. These drugs improve the efficacy while reducing the incidence of adverse reactions. In addition, some drugs have been shown to significantly reduce the risk of thrombotic events.

The elderly are at high risk of atrial fibrillation, and the aging of the population worldwide has exacerbated the incidence of atrial fibrillation. With the advent of an aging society, the number of people suffering from cardiovascular diseases continues to increase, especially in developed countries. This trend has directly driven the demand for atrial fibrillation treatment drugs. According to a report by the World Health Organization (WHO), by 2050, the population aged 65 and above is expected to increase to 16% of the global population, which brings huge growth space for the atrial fibrillation drug market. Direct oral anticoagulants (DOACs) such as rivaroxaban, apixaban, dabigatran, etc., have rapidly occupied the market with their higher safety and less monitoring requirements than traditional drugs (such as warfarin). This type of new drug significantly reduces the risk and inconvenience of medication for patients and promotes the replacement of atrial fibrillation treatment drugs. The widespread use of DOACs has brought market expansion opportunities for pharmaceutical companies, while also reducing patients' medication compliance problems and promoting R&D investment in this field. Advances in modern medical technology, such as the concept of precision medicine based on genetic testing and personalized treatment, have gradually penetrated into the development of atrial fibrillation drugs. This makes it possible to personalize medicines for different patients’ specific genes and health conditions, further improving treatment outcomes. For example, through genetic screening, doctors can more accurately determine how patients metabolize anticoagulants, thereby selecting the most suitable drugs and avoiding the risk of adverse reactions and drug failure.

This report delivers a comprehensive overview of the global Atrial Fibrillation Drugs market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Atrial Fibrillation Drugs. The Atrial Fibrillation Drugs market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.

The report segments the global Atrial Fibrillation Drugs market comprehensively. Regional market sizes by Type, by Application, , and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.

This report will assist Atrial Fibrillation Drugs manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Market Segmentation

Scope of Atrial Fibrillation Drugs Market Report

Chapter Outline

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Atrial Fibrillation Drugs Market Size Growth Rate by Type: 2021 vs 2025 vs 2032

1.2.2 Anticoagulants

1.2.3 Antiarrhythmic Drugs

1.3 Market by Application

1.3.1 Global Atrial Fibrillation Drugs Market Growth by Application: 2021 vs 2025 vs 2032

1.3.2 Retail Pharmacy

1.3.3 Hospital Pharmacy

1.3.4 Online Pharmacy

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2.1 Global Atrial Fibrillation Drugs Market Perspective (2021–2032)

2.2 Global Atrial Fibrillation Drugs Growth Trends by Region

2.2.1 Global Atrial Fibrillation Drugs Market Size by Region: 2021 vs 2025 vs 2032

2.2.2 Atrial Fibrillation Drugs Historic Market Size by Region (2021–2026)

2.2.3 Atrial Fibrillation Drugs Forecasted Market Size by Region (2027–2032)

2.3 Atrial Fibrillation Drugs Market Dynamics

2.3.1 Atrial Fibrillation Drugs Industry Trends

2.3.2 Atrial Fibrillation Drugs Market Drivers

2.3.3 Atrial Fibrillation Drugs Market Challenges

2.3.4 Atrial Fibrillation Drugs Market Restraints

3.1 Global Top Atrial Fibrillation Drugs Players by Revenue

3.1.1 Global Top Atrial Fibrillation Drugs Players by Revenue (2021–2026)

3.1.2 Global Atrial Fibrillation Drugs Revenue Market Share by Players (2021–2026)

3.2 Global Top Atrial Fibrillation Drugs Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)

3.3 Global Key Players Ranking by Atrial Fibrillation Drugs Revenue

3.4 Global Atrial Fibrillation Drugs Market Concentration Ratio

3.4.1 Global Atrial Fibrillation Drugs Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Atrial Fibrillation Drugs Revenue in 2025

3.5 Global Key Players of Atrial Fibrillation Drugs Head Offices and Areas Served

3.6 Global Key Players of Atrial Fibrillation Drugs, Products and Applications

3.7 Global Key Players of Atrial Fibrillation Drugs, Date of General Availability (GA)

3.8 Mergers and Acquisitions, Expansion Plans

4.1 Global Atrial Fibrillation Drugs Historic Market Size by Type (2021–2026)

4.2 Global Atrial Fibrillation Drugs Forecasted Market Size by Type (2027–2032)

5.1 Global Atrial Fibrillation Drugs Historic Market Size by Application (2021–2026)

5.2 Global Atrial Fibrillation Drugs Forecasted Market Size by Application (2027–2032)

6.1 North America Atrial Fibrillation Drugs Market Size (2021–2032)

6.2 North America Atrial Fibrillation Drugs Market Growth Rate by Country: 2021 vs 2025 vs 2032

6.3 North America Atrial Fibrillation Drugs Market Size by Country (2021–2026)

6.4 North America Atrial Fibrillation Drugs Market Size by Country (2027–2032)

6.5 United States

6.6 Canada

7.1 Europe Atrial Fibrillation Drugs Market Size (2021–2032)

7.2 Europe Atrial Fibrillation Drugs Market Growth Rate by Country: 2021 vs 2025 vs 2032

7.3 Europe Atrial Fibrillation Drugs Market Size by Country (2021–2026)

7.4 Europe Atrial Fibrillation Drugs Market Size by Country (2027–2032)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Ireland

8.1 Asia-Pacific Atrial Fibrillation Drugs Market Size (2021–2032)

8.2 Asia-Pacific Atrial Fibrillation Drugs Market Growth Rate by Region: 2021 vs 2025 vs 2032

8.3 Asia-Pacific Atrial Fibrillation Drugs Market Size by Region (2021–2026)

8.4 Asia-Pacific Atrial Fibrillation Drugs Market Size by Region (2027–2032)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia & New Zealand

9.1 Latin America Atrial Fibrillation Drugs Market Size (2021–2032)

9.2 Latin America Atrial Fibrillation Drugs Market Growth Rate by Country: 2021 vs 2025 vs 2032

9.3 Latin America Atrial Fibrillation Drugs Market Size by Country (2021–2026)

9.4 Latin America Atrial Fibrillation Drugs Market Size by Country (2027–2032)

9.5 Mexico

9.6 Brazil

10.1 Middle East & Africa Atrial Fibrillation Drugs Market Size (2021–2032)

10.2 Middle East & Africa Atrial Fibrillation Drugs Market Growth Rate by Country: 2021 vs 2025 vs 2032

10.3 Middle East & Africa Atrial Fibrillation Drugs Market Size by Country (2021–2026)

10.4 Middle East & Africa Atrial Fibrillation Drugs Market Size by Country (2027–2032)

10.5 Israel

10.6 Saudi Arabia

10.7 UAE

11.1 Pfizer

11.1.1 Pfizer Company Details

11.1.2 Pfizer Business Overview

11.1.3 Pfizer Atrial Fibrillation Drugs Introduction

11.1.4 Pfizer Revenue in Atrial Fibrillation Drugs Business (2021–2026)

11.1.5 Pfizer Recent Development

11.2 Johnson & Johnson

11.2.1 Johnson & Johnson Company Details

11.2.2 Johnson & Johnson Business Overview

11.2.3 Johnson & Johnson Atrial Fibrillation Drugs Introduction

11.2.4 Johnson & Johnson Revenue in Atrial Fibrillation Drugs Business (2021–2026)

11.2.5 Johnson & Johnson Recent Development

11.3 Sanofi

11.3.1 Sanofi Company Details

11.3.2 Sanofi Business Overview

11.3.3 Sanofi Atrial Fibrillation Drugs Introduction

11.3.4 Sanofi Revenue in Atrial Fibrillation Drugs Business (2021–2026)

11.3.5 Sanofi Recent Development

11.4 Daiichi Sankyo

11.4.1 Daiichi Sankyo Company Details

11.4.2 Daiichi Sankyo Business Overview

11.4.3 Daiichi Sankyo Atrial Fibrillation Drugs Introduction

11.4.4 Daiichi Sankyo Revenue in Atrial Fibrillation Drugs Business (2021–2026)

11.4.5 Daiichi Sankyo Recent Development

11.5 Teva Pharmaceuticals

11.5.1 Teva Pharmaceuticals Company Details

11.5.2 Teva Pharmaceuticals Business Overview

11.5.3 Teva Pharmaceuticals Atrial Fibrillation Drugs Introduction

11.5.4 Teva Pharmaceuticals Revenue in Atrial Fibrillation Drugs Business (2021–2026)

11.5.5 Teva Pharmaceuticals Recent Development

11.6 Sandoz

11.6.1 Sandoz Company Details

11.6.2 Sandoz Business Overview

11.6.3 Sandoz Atrial Fibrillation Drugs Introduction

11.6.4 Sandoz Revenue in Atrial Fibrillation Drugs Business (2021–2026)

11.6.5 Sandoz Recent Development

11.7 Glenmark Pharmaceuticals

11.7.1 Glenmark Pharmaceuticals Company Details

11.7.2 Glenmark Pharmaceuticals Business Overview

11.7.3 Glenmark Pharmaceuticals Atrial Fibrillation Drugs Introduction

11.7.4 Glenmark Pharmaceuticals Revenue in Atrial Fibrillation Drugs Business (2021–2026)

11.7.5 Glenmark Pharmaceuticals Recent Development

11.8 ANI Pharmaceuticals

11.8.1 ANI Pharmaceuticals Company Details

11.8.2 ANI Pharmaceuticals Business Overview

11.8.3 ANI Pharmaceuticals Atrial Fibrillation Drugs Introduction

11.8.4 ANI Pharmaceuticals Revenue in Atrial Fibrillation Drugs Business (2021–2026)

11.8.5 ANI Pharmaceuticals Recent Development

11.9 Anhui Fengyuan Pharmaceutical

11.9.1 Anhui Fengyuan Pharmaceutical Company Details

11.9.2 Anhui Fengyuan Pharmaceutical Business Overview

11.9.3 Anhui Fengyuan Pharmaceutical Atrial Fibrillation Drugs Introduction

11.9.4 Anhui Fengyuan Pharmaceutical Revenue in Atrial Fibrillation Drugs Business (2021–2026)

11.9.5 Anhui Fengyuan Pharmaceutical Recent Development

11.10 Jiuxu Pharmaceutical Group

11.10.1 Jiuxu Pharmaceutical Group Company Details

11.10.2 Jiuxu Pharmaceutical Group Business Overview

11.10.3 Jiuxu Pharmaceutical Group Atrial Fibrillation Drugs Introduction

11.10.4 Jiuxu Pharmaceutical Group Revenue in Atrial Fibrillation Drugs Business (2021–2026)

11.10.5 Jiuxu Pharmaceutical Group Recent Development

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

List of Tables

 Table 1. Global Atrial Fibrillation Drugs Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032

 Table 2. Key Players of Anticoagulants

 Table 3. Key Players of Antiarrhythmic Drugs

 Table 4. Global Atrial Fibrillation Drugs Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032

 Table 5. Global Atrial Fibrillation Drugs Market Size by Region (US$ Million): 2021 vs 2025 vs 2032

 Table 6. Global Atrial Fibrillation Drugs Market Size by Region (US$ Million), 2021–2026

 Table 7. Global Atrial Fibrillation Drugs Market Share by Region (2021–2026)

 Table 8. Global Atrial Fibrillation Drugs Forecasted Market Size by Region (US$ Million), 2027–2032

 Table 9. Global Atrial Fibrillation Drugs Market Share by Region (2027–2032)

 Table 10. Atrial Fibrillation Drugs Market Trends

 Table 11. Atrial Fibrillation Drugs Market Drivers

 Table 12. Atrial Fibrillation Drugs Market Challenges

 Table 13. Atrial Fibrillation Drugs Market Restraints

 Table 14. Global Atrial Fibrillation Drugs Revenue by Players (US$ Million), 2021–2026

 Table 15. Global Atrial Fibrillation Drugs Market Share by Players (2021–2026)

 Table 16. Global Top Atrial Fibrillation Drugs Players by Tier (Tier 1, Tier 2, and Tier 3), based on Atrial Fibrillation Drugs Revenue, 2025

 Table 17. Ranking of Global Top Atrial Fibrillation Drugs Companies by Revenue (US$ Million) in 2025

 Table 18. Global 5 Largest Players Market Share by Atrial Fibrillation Drugs Revenue (CR5 and HHI), 2021–2026

 Table 19. Global Key Players of Atrial Fibrillation Drugs, Headquarters and Area Served

 Table 20. Global Key Players of Atrial Fibrillation Drugs, Products and Applications

 Table 21. Global Key Players of Atrial Fibrillation Drugs, Date of General Availability (GA)

 Table 22. Mergers and Acquisitions, Expansion Plans

 Table 23. Global Atrial Fibrillation Drugs Market Size by Type (US$ Million), 2021–2026

 Table 24. Global Atrial Fibrillation Drugs Revenue Market Share by Type (2021–2026)

 Table 25. Global Atrial Fibrillation Drugs Forecasted Market Size by Type (US$ Million), 2027–2032

 Table 26. Global Atrial Fibrillation Drugs Revenue Market Share by Type (2027–2032)

 Table 27. Global Atrial Fibrillation Drugs Market Size by Application (US$ Million), 2021–2026

 Table 28. Global Atrial Fibrillation Drugs Revenue Market Share by Application (2021–2026)

 Table 29. Global Atrial Fibrillation Drugs Forecasted Market Size by Application (US$ Million), 2027–2032

 Table 30. Global Atrial Fibrillation Drugs Revenue Market Share by Application (2027–2032)

 Table 31. North America Atrial Fibrillation Drugs Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

 Table 32. North America Atrial Fibrillation Drugs Market Size by Country (US$ Million), 2021–2026

 Table 33. North America Atrial Fibrillation Drugs Market Size by Country (US$ Million), 2027–2032

 Table 34. Europe Atrial Fibrillation Drugs Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

 Table 35. Europe Atrial Fibrillation Drugs Market Size by Country (US$ Million), 2021–2026

 Table 36. Europe Atrial Fibrillation Drugs Market Size by Country (US$ Million), 2027–2032

 Table 37. Asia-Pacific Atrial Fibrillation Drugs Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032

 Table 38. Asia-Pacific Atrial Fibrillation Drugs Market Size by Region (US$ Million), 2021–2026

 Table 39. Asia-Pacific Atrial Fibrillation Drugs Market Size by Region (US$ Million), 2027–2032

 Table 40. Latin America Atrial Fibrillation Drugs Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

 Table 41. Latin America Atrial Fibrillation Drugs Market Size by Country (US$ Million), 2021–2026

 Table 42. Latin America Atrial Fibrillation Drugs Market Size by Country (US$ Million), 2027–2032

 Table 43. Middle East & Africa Atrial Fibrillation Drugs Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

 Table 44. Middle East & Africa Atrial Fibrillation Drugs Market Size by Country (US$ Million), 2021–2026

 Table 45. Middle East & Africa Atrial Fibrillation Drugs Market Size by Country (US$ Million), 2027–2032

 Table 46. Pfizer Company Details

 Table 47. Pfizer Business Overview

 Table 48. Pfizer Atrial Fibrillation Drugs Product

 Table 49. Pfizer Revenue in Atrial Fibrillation Drugs Business (US$ Million), 2021–2026

 Table 50. Pfizer Recent Development

 Table 51. Johnson & Johnson Company Details

 Table 52. Johnson & Johnson Business Overview

 Table 53. Johnson & Johnson Atrial Fibrillation Drugs Product

 Table 54. Johnson & Johnson Revenue in Atrial Fibrillation Drugs Business (US$ Million), 2021–2026

 Table 55. Johnson & Johnson Recent Development

 Table 56. Sanofi Company Details

 Table 57. Sanofi Business Overview

 Table 58. Sanofi Atrial Fibrillation Drugs Product

 Table 59. Sanofi Revenue in Atrial Fibrillation Drugs Business (US$ Million), 2021–2026

 Table 60. Sanofi Recent Development

 Table 61. Daiichi Sankyo Company Details

 Table 62. Daiichi Sankyo Business Overview

 Table 63. Daiichi Sankyo Atrial Fibrillation Drugs Product

 Table 64. Daiichi Sankyo Revenue in Atrial Fibrillation Drugs Business (US$ Million), 2021–2026

 Table 65. Daiichi Sankyo Recent Development

 Table 66. Teva Pharmaceuticals Company Details

 Table 67. Teva Pharmaceuticals Business Overview

 Table 68. Teva Pharmaceuticals Atrial Fibrillation Drugs Product

 Table 69. Teva Pharmaceuticals Revenue in Atrial Fibrillation Drugs Business (US$ Million), 2021–2026

 Table 70. Teva Pharmaceuticals Recent Development

 Table 71. Sandoz Company Details

 Table 72. Sandoz Business Overview

 Table 73. Sandoz Atrial Fibrillation Drugs Product

 Table 74. Sandoz Revenue in Atrial Fibrillation Drugs Business (US$ Million), 2021–2026

 Table 75. Sandoz Recent Development

 Table 76. Glenmark Pharmaceuticals Company Details

 Table 77. Glenmark Pharmaceuticals Business Overview

 Table 78. Glenmark Pharmaceuticals Atrial Fibrillation Drugs Product

 Table 79. Glenmark Pharmaceuticals Revenue in Atrial Fibrillation Drugs Business (US$ Million), 2021–2026

 Table 80. Glenmark Pharmaceuticals Recent Development

 Table 81. ANI Pharmaceuticals Company Details

 Table 82. ANI Pharmaceuticals Business Overview

 Table 83. ANI Pharmaceuticals Atrial Fibrillation Drugs Product

 Table 84. ANI Pharmaceuticals Revenue in Atrial Fibrillation Drugs Business (US$ Million), 2021–2026

 Table 85. ANI Pharmaceuticals Recent Development

 Table 86. Anhui Fengyuan Pharmaceutical Company Details

 Table 87. Anhui Fengyuan Pharmaceutical Business Overview

 Table 88. Anhui Fengyuan Pharmaceutical Atrial Fibrillation Drugs Product

 Table 89. Anhui Fengyuan Pharmaceutical Revenue in Atrial Fibrillation Drugs Business (US$ Million), 2021–2026

 Table 90. Anhui Fengyuan Pharmaceutical Recent Development

 Table 91. Jiuxu Pharmaceutical Group Company Details

 Table 92. Jiuxu Pharmaceutical Group Business Overview

 Table 93. Jiuxu Pharmaceutical Group Atrial Fibrillation Drugs Product

 Table 94. Jiuxu Pharmaceutical Group Revenue in Atrial Fibrillation Drugs Business (US$ Million), 2021–2026

 Table 95. Jiuxu Pharmaceutical Group Recent Development

 Table 96. Research Programs/Design for This Report

 Table 97. Key Data Information from Secondary Sources

 Table 98. Key Data Information from Primary Sources

 Table 99. Authors List of This Report

List of Figures

 Figure 1. Atrial Fibrillation Drugs Picture

 Figure 2. Global Atrial Fibrillation Drugs Market Size Comparison by Type (US$ Million), 2021–2032

 Figure 3. Global Atrial Fibrillation Drugs Market Share by Type: 2025 vs 2032

 Figure 4. Anticoagulants Features

 Figure 5. Antiarrhythmic Drugs Features

 Figure 6. Global Atrial Fibrillation Drugs Market Size by Application (US$ Million), 2021–2032

 Figure 7. Global Atrial Fibrillation Drugs Market Share by Application: 2025 vs 2032

 Figure 8. Retail Pharmacy Case Studies

 Figure 9. Hospital Pharmacy Case Studies

 Figure 10. Online Pharmacy Case Studies

 Figure 11. Atrial Fibrillation Drugs Report Years Considered

 Figure 12. Global Atrial Fibrillation Drugs Market Size (US$ Million), Year-over-Year: 2021–2032

 Figure 13. Global Atrial Fibrillation Drugs Market Size, (US$ Million), 2021 vs 2025 vs 2032

 Figure 14. Global Atrial Fibrillation Drugs Market Share by Region: 2025 vs 2032

 Figure 15. Global Atrial Fibrillation Drugs Market Share by Players in 2025

 Figure 16. Global Atrial Fibrillation Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

 Figure 17. The Top 10 and 5 Players Market Share by Atrial Fibrillation Drugs Revenue in 2025

 Figure 18. North America Atrial Fibrillation Drugs Market Size YoY Growth (US$ Million), 2021–2032

 Figure 19. North America Atrial Fibrillation Drugs Market Share by Country (2021–2032)

 Figure 20. United States Atrial Fibrillation Drugs Market Size YoY Growth (US$ Million), 2021–2032

 Figure 21. Canada Atrial Fibrillation Drugs Market Size YoY Growth (US$ Million), 2021–2032

 Figure 22. Europe Atrial Fibrillation Drugs Market Size YoY Growth (US$ Million), 2021–2032

 Figure 23. Europe Atrial Fibrillation Drugs Market Share by Country (2021–2032)

 Figure 24. Germany Atrial Fibrillation Drugs Market Size YoY Growth (US$ Million), 2021–2032

 Figure 25. France Atrial Fibrillation Drugs Market Size YoY Growth (US$ Million), 2021–2032

 Figure 26. U.K. Atrial Fibrillation Drugs Market Size YoY Growth (US$ Million), 2021–2032

 Figure 27. Italy Atrial Fibrillation Drugs Market Size YoY Growth (US$ Million), 2021–2032

 Figure 28. Russia Atrial Fibrillation Drugs Market Size YoY Growth (US$ Million), 2021–2032

 Figure 29. Ireland Atrial Fibrillation Drugs Market Size YoY Growth (US$ Million), 2021–2032

 Figure 30. Asia-Pacific Atrial Fibrillation Drugs Market Size YoY Growth (US$ Million), 2021–2032

 Figure 31. Asia-Pacific Atrial Fibrillation Drugs Market Share by Region (2021–2032)

 Figure 32. China Atrial Fibrillation Drugs Market Size YoY Growth (US$ Million), 2021–2032

 Figure 33. Japan Atrial Fibrillation Drugs Market Size YoY Growth (US$ Million), 2021–2032

 Figure 34. South Korea Atrial Fibrillation Drugs Market Size YoY Growth (US$ Million), 2021–2032

 Figure 35. Southeast Asia Atrial Fibrillation Drugs Market Size YoY Growth (US$ Million), 2021–2032

 Figure 36. India Atrial Fibrillation Drugs Market Size YoY Growth (US$ Million), 2021–2032

 Figure 37. Australia & New Zealand Atrial Fibrillation Drugs Market Size YoY Growth (US$ Million), 2021–2032

 Figure 38. Latin America Atrial Fibrillation Drugs Market Size YoY Growth (US$ Million), 2021–2032

 Figure 39. Latin America Atrial Fibrillation Drugs Market Share by Country (2021–2032)

 Figure 40. Mexico Atrial Fibrillation Drugs Market Size YoY Growth (US$ Million), 2021–2032

 Figure 41. Brazil Atrial Fibrillation Drugs Market Size YoY Growth (US$ Million), 2021–2032

 Figure 42. Middle East & Africa Atrial Fibrillation Drugs Market Size YoY Growth (US$ Million), 2021–2032

 Figure 43. Middle East & Africa Atrial Fibrillation Drugs Market Share by Country (2021–2032)

 Figure 44. Israel Atrial Fibrillation Drugs Market Size YoY Growth (US$ Million), 2021–2032

 Figure 45. Saudi Arabia Atrial Fibrillation Drugs Market Size YoY Growth (US$ Million), 2021–2032

 Figure 46. UAE Atrial Fibrillation Drugs Market Size YoY Growth (US$ Million), 2021–2032

 Figure 47. Pfizer Revenue Growth Rate in Atrial Fibrillation Drugs Business (2021–2026)

 Figure 48. Johnson & Johnson Revenue Growth Rate in Atrial Fibrillation Drugs Business (2021–2026)

 Figure 49. Sanofi Revenue Growth Rate in Atrial Fibrillation Drugs Business (2021–2026)

 Figure 50. Daiichi Sankyo Revenue Growth Rate in Atrial Fibrillation Drugs Business (2021–2026)

 Figure 51. Teva Pharmaceuticals Revenue Growth Rate in Atrial Fibrillation Drugs Business (2021–2026)

 Figure 52. Sandoz Revenue Growth Rate in Atrial Fibrillation Drugs Business (2021–2026)

 Figure 53. Glenmark Pharmaceuticals Revenue Growth Rate in Atrial Fibrillation Drugs Business (2021–2026)

 Figure 54. ANI Pharmaceuticals Revenue Growth Rate in Atrial Fibrillation Drugs Business (2021–2026)

 Figure 55. Anhui Fengyuan Pharmaceutical Revenue Growth Rate in Atrial Fibrillation Drugs Business (2021–2026)

 Figure 56. Jiuxu Pharmaceutical Group Revenue Growth Rate in Atrial Fibrillation Drugs Business (2021–2026)

 Figure 57. Bottom-up and Top-down Approaches for This Report

 Figure 58. Data Triangulation

 Figure 59. Key Executives Interviewed